LBA
HUMA icon

Letko, Brosseau & Associates’s Humacyte HUMA Stock Holding History

Letko, Brosseau & Associates’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.9K Hold
45,950
– – ﹤0.01% 111
2026
Q1 		$27.9K Hold
45,950
– – ﹤0.01% 100
2025
Q4 		$44.1K Hold
45,950
– – ﹤0.01% 99
2025
Q3 		$80K Hold
45,950
– – ﹤0.01% 96
2025
Q2 		$96K Buy
45,950
+21,150
+85% +$40.6K ﹤0.01% 92
2025
Q1 		$42.3K Buy
+24,800
New +$93.1K ﹤0.01% 87

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Letko, Brosseau & Associates's HUMA Position: Q2 2026 in Review

Letko, Brosseau & Associates held its Humacyte (HUMA) position steady in Q2 2026 at 45,950 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #111.

Letko, Brosseau & Associates first reported a position in HUMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $96K in Q2 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Letko, Brosseau & Associates held 45,950 shares of Humacyte worth $35.9K as of Q2 2026.
  • Letko, Brosseau & Associates left its Humacyte share count unchanged in Q2 2026.
  • Humacyte made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #111 holding.
  • Letko, Brosseau & Associates first reported a position in Humacyte in Q1 2025 and has held it in 6 quarters since.
  • Letko, Brosseau & Associates's Humacyte position peaked at $96K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.